Sarepta Therapeutics, Inc. (SRPT) Stock Analysis

Q: What is the SRPT stock price target?

Take-profit $19.80 (+15.5% upside). Prior stop was $16.07.

Q: Is SRPT overvalued or undervalued?

Sarepta Therapeutics, Inc. trades at a P/E of 47.5 (forward 6.1). TrendMatrix value score: 7.1/10. Overall verdict: Sell.

Q: What do analysts say about SRPT?

33 analysts cover SRPT with a consensus score of 3.4/5. Average price target: $22.

SellModerate ConfidenceUpdated 1 hr ago (May 20, 2026, 3:46 PM ET)

Healthcare · Biotechnology

Sarepta Therapeutics is a commercial-stage biopharma with four FDA-approved Duchenne muscular dystrophy products (EXONDYS 51, VYONDYS 53, AMONDYS 45, ELEVIDYS), generating $1,864.3M in net revenues in 2025. All products rely on third-party CMOs for manufacturing as Sarepta has... Read more

$17.13+15.5% A.UpsideScore 4.6/10#125 of 157 Biotechnology

QualityF-score7 / 9FCF yield11.66%

Stop $16.07Target $19.80(analyst − 10%)A.R:R 1.1:1

Analyst target$22.00+28.4%23 analysts

$19.80our TP

$17.13price

$22.00mean

$38

Sell if holding. Engine safety override at $17.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 28%; Elevated put/call ratio: 2.25; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.

Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.

Recent Developments — Sarepta Therapeutics, Inc.

Latest news

Watching Sarepta Therapeutics, Disc Medicine; Shares See Volume To The Upside After WSJ Reports "Trump Planning to Fire — benzinga May 8, 2026 positive
Earnings Scheduled For May 6, 2026 — benzinga May 6, 2026 neutral
Sarepta Therapeutics Q1 Adj. EPS $3.16 Beats $0.99 Estimate, Sales $730.803M Beat $474.155M Estimate — benzinga May 6, 2026 positive
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target — benzinga Apr 16, 2026 negative
9 Health Care Stocks With Whale Alerts In Today's Session — benzinga Apr 7, 2026 positive

Generated 2026-05-20T21:06:21Z.

Thesis

Rewards

No bull case signals

Risks

Concentration risk — Supplier: Catalent (ELEVIDYS commercial CMO)

Concentration risk — Supplier: Aldevron (plasmid supplier for ELEVIDYS)

Risk below floor (2.8 < 3.0)

Key Metrics

P/E (TTM)47.5

P/E (Fwd)6.1

Mkt Cap$1.8B

EV/EBITDA46.6

Profit Mgn3.0%

ROE4.9%

Rev Growth-1.9%

Beta0.26

DividendNone

Rating analysts33

Quality Signals

Piotroski F7/9

Options Flow

P/C2.25bearish

IV70%elevated

Max Pain$11-35.8% vs spot

Concentration Risks(10-K Item 1A)

HIGHSupplierCatalent (ELEVIDYS commercial CMO)
10-K Item 1: 'Catalent supports our clinical and commercial manufacturing demand for ELEVIDYS and our SRP-9003 LGMD program'
HIGHSupplierAldevron (plasmid supplier for ELEVIDYS)
10-K Item 1: 'Aldevron provides plasmids for ELEVIDYS and SRP-9003 and is expected to provide plasmid source material for any future gene therapy programs.'

Material Events(8-K, last 90d)

2026-02-25Item 5.02HIGH
CEO Douglas Ingram notified the Company of his decision to retire as CEO by end of 2026 or upon appointment of his replacement. Search for internal and external candidates commenced. No successor named.
SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value7.115%1.06

Quality5.415%0.81

Growth2.015%0.30

Momentum1.310%0.13

Sentiment6.110%0.61

Insider Activity5.010%0.50

Peer Rank3.810%0.38

Technical Setup6.05%0.30

Risk Profile2.85%0.14

Catalyst6.75%0.34

Overall (Σ contributions)4.57

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd

0.0

Volume

0.0

Obv

1.0

Ma Position

2.2

Rsi

3.5

Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.7%/30d) — pullback in uptrend, not confirmed weakness

Revenue shrinking — -1.9% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth

2.0

Declining revenue: -2%

Low model confidence on this dimension (33%).

Volatile — 6.8% daily ATR makes tight stops impractical. Position-size conservatively.static

Days To Cover

0.0

Volatility

0.0

Put Call

0.0

Short Interest

0.7

Implied Vol

1.6

Max Pain Risk

3.0

Debt Equity

6.8

Beta

10.0

High short interest justified: 28%Elevated put/call: 2.25High IV: 70%Above max pain $11Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank

3.1

Value Rank

6.0

Quality Rank

6.3

GatesMomentum 1.3<4.5A.R:R 1.1 < 1.5@spotInsider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 77d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive

RSI

30 · Neutral

↓ 20D MA↓ 50D MA↓ 200D MAGOLDEN CROSSSupport $16.57Resistance $23.49

Price Targets

$16

$20

A.Upside+15.6%

A.R:R1.1:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Risk below floor (2.8 < 3.0)

! Momentum score 1.3/10 — below 4.5 minimum

! Reward/Risk 1.1:1 at current price — below 1.5:1 minimum

Earnings

3/4 beats

Next Earnings2026-08-05 (77d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is SRPT stock a buy right now?

Sell if holding. Engine safety override at $17.13: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10. Specifically: High short interest: 28%; Elevated put/call ratio: 2.25; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $16.07. Score 4.6/10, moderate confidence.

What is the SRPT stock price target?

Take-profit target: $19.80 (+15.5% upside). Prior stop was $16.07. Stop-loss: $16.07.

What are the risks of investing in SRPT?

Concentration risk — Supplier: Catalent (ELEVIDYS commercial CMO); Concentration risk — Supplier: Aldevron (plasmid supplier for ELEVIDYS); Risk below floor (2.8 < 3.0).

Is SRPT overvalued or undervalued?

Sarepta Therapeutics, Inc. trades at a P/E of 47.5 (forward 6.1). TrendMatrix value score: 7.1/10. Verdict: Sell.

What do analysts say about SRPT?

33 analysts cover SRPT with a consensus score of 3.4/5. Average price target: $22.

What does Sarepta Therapeutics, Inc. do?Sarepta Therapeutics is a commercial-stage biopharma with four FDA-approved Duchenne muscular dystrophy products...